Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 349 (2): 146—53. doi:10.1056/NEJMoa025313. PMID12853587. (англ.)
The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011). Dalteparin versus unfractionated heparin in critically ill patients. doi:10.1056/NEJMoa1014475. (англ.)
Douketis J, Cook D, Meade M та ін. (2008). Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin. Arch Intern Med. 168 (16): 1805—1812. doi:10.1001/archinte.168.16.1805. PMID18779469. (англ.)
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 349 (2): 146—53. doi:10.1056/NEJMoa025313. PMID12853587. (англ.)
Douketis J, Cook D, Meade M та ін. (2008). Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin. Arch Intern Med. 168 (16): 1805—1812. doi:10.1001/archinte.168.16.1805. PMID18779469. (англ.)
